Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Accelerating global pet humanization, increased diagnostic utilization per clinical visit, and ongoing margin expansion drive sustained double-digit earnings growth.
Severe Valuation Compression: Market recalibrates the extreme 39x trailing P/E multiple down to the model's 25x terminal multiple constraint.
IDEXX is a highly profitable, dominant player in companion animal diagnostics. Its razor-and-blade model locks in veterinary clinics, driving recurring consumable revenue with substantial switching costs and pricing power.
IDEXX is a highly profitable, dominant player in companion animal diagnostics. Its razor-and-blade model locks in veterinary clinics, driving recurring consumable revenue with substantial switching costs and pricing power.
Razor-and-blade diagnostic instrument model
High switching costs locking in veterinary clinics
Accelerating global pet humanization, increased diagnostic utilization per clinical visit, and ongoing margin expansion from software integration.
Sell. Despite exceptional business quality, the extreme valuation multiple and an 8.1pp implied growth gap severely dampen confidence.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
A prolonged macroeconomic downturn could reduce discretionary veterinary clinic traffic, stalling instrument placements and consumable volume growth, while a high starting valuation multiple compresses.
Razor-and-blade diagnostic instrument model
High switching costs locking in veterinary clinics
Pricing power driving 41.7% ROIC
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $1.1B after capex $137.7M, with terminal value at 57.2% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
Monitor quarterly consumable volume growth and operating margin stability to validate pricing power against macro headwinds.
Monitor quarterly consumable volume growth and operating margin stability to validate pricing power against macro headwinds.
Monitor quarterly consumable volume growth and operating margin stability to validate against macro headwinds.
Highly efficient model with low maintenance capex, driving strong owner earnings and exceptional 41.7% ROIC.
Accelerating global pet humanization, increased diagnostic utilization per clinical visit, and ongoing margin expansion from software integration.
Macroeconomic downturns reducing discretionary clinic traffic and delaying capital expenditures by veterinary practices.
Highly efficient model with low maintenance capex, driving strong owner earnings and exceptional 41.7% ROIC.
Zero weight or significant underweight due to the massive 37.24% downside to fair value.
Take profits or exit positions to avoid the extreme 8.1pp implied growth gap and impending valuation compression risk.
Upside case depends on the report valuation range and named growth catalysts.
internal valuation cross-checks of $709 implies near 15-20% sustained long-term growth and a terminal multiple well into the 30s-40s, while intrinsic valuation supports a $335 midpoint.
Sell. The composite midpoint is massively lower than the valuation cross-checks, driven by conservative terminal multiple constraints (25x) and a severe growth gap.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
A prolonged macroeconomic downturn reduces discretionary veterinary traffic, stalling instrument placements and driving severe multiple compression.
Market recalibrates the extreme 39x trailing P/E multiple down to the model's 25x terminal multiple constraint.
A prolonged recession reduces discretionary veterinary clinic traffic, stalling instrument placements and recurring consumable volumes.
Competition forces aggressive pricing, causing operating margins to fall below the historically stable 30-31.6% range.
The five developments that would weaken our investment case.
High operating margins reflect the strong proprietary pricing power of companion animal diagnostic systems. Margin slippage signals escalating competitive pressure or aggressive discounting on instruments and assays, undermining operating leverage and dampening corporate profitability.
Current:31.6% for the period ended 2025-12-31
Alert ifFalls below 30.0% over two consecutive quarters
The core razor-and-blade business model relies on high-margin diagnostic consumable test volumes running on an expanding installed instrument base. Reduced veterinary clinic patient traffic cuts recurring consumable purchases, slowing top-line expansion and eroding the recurring cash generation profile.
Current:10.4% for the period ended 2025-12-31
Alert ifDecelerates below 5.0% year-over-year over two consecutive quarters
Stalling placement velocity of point-of-care diagnostic analyzers limits the addressable pool for future recurring consumable utilization. If instrument placement stagnation necessitates heavy promotional subsidies, gross margins degrade and long-term diagnostic test sales growth decelerates.
Current:61.8% for the period ended 2025-12-31
Alert ifCompresses below 58.0% over any four-quarter measurement window
Premium valuation multiples demand superior and consistent cash flow generation to justify growth expectations. A breakdown in cash conversion indicates earnings quality impairment or rising working capital requirements, triggering valuation reassessments when premium expectations are unmet.
Current:1.115 as of the 2026-05-13 analysis date
Exceptional returns on invested capital justify premium market multiples for the veterinary diagnostics leader. Any structural compression in capital returns impairs economic value added, forcing valuation multiples to de-rate toward broader market averages and eroding shareholder returns.
Current:41.7% as of the 2026-05-13 analysis date
Alert ifDrops below 35.0% over any trailing twelve-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
This edition does not contain enough finite inputs to reproduce the lens calculation.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Accelerating global pet humanization, increased diagnostic utilization per clinical visit, and ongoing margin expansion drive sustained double-digit earnings growth.
IDEXX maintains dominant market share and high ROIC, but baseline growth fades to 4.5% and the valuation multiple compresses to a realistic 25x premium exit multiple.
Monitor quarterly consumable volume growth and operating margin stability to validate pricing power against macro headwinds.
Warning level: Falls below 30.0% over two consecutive quarters. High operating margins reflect the strong proprietary pricing power of companion animal diagnostic systems. Margin slippage signals escalating competitive pressure or aggressive discounting on instruments and assays, undermining operating leverage and dampening corporate profitability.
Warning level: Decelerates below 5.0% year-over-year over two consecutive quarters. The core razor-and-blade business model relies on high-margin diagnostic consumable test volumes running on an expanding installed instrument base. Reduced veterinary clinic patient traffic cuts recurring consumable purchases, slowing top-line expansion and eroding the recurring cash generation profile.
Warning level: Compresses below 58.0% over any four-quarter measurement window. Stalling placement velocity of point-of-care diagnostic analyzers limits the addressable pool for future recurring consumable utilization. If instrument placement stagnation necessitates heavy promotional subsidies, gross margins degrade and long-term diagnostic test sales growth decelerates.
Warning level: Falls below 1.0x over any trailing twelve-month period. Premium valuation multiples demand superior and consistent cash flow generation to justify growth expectations. A breakdown in cash conversion indicates earnings quality impairment or rising working capital requirements, triggering valuation reassessments when premium expectations are unmet.
Warning level: Drops below 35.0% over any trailing twelve-month period. Exceptional returns on invested capital justify premium market multiples for the veterinary diagnostics leader. Any structural compression in capital returns impairs economic value added, forcing valuation multiples to de-rate toward broader market averages and eroding shareholder returns.
| $3.22B |
| $3.37B |
| $3.66B |
| $3.90B |
| $4.30B |
| +7.6% |
| Gross profit | $1.89B | $2.00B | $2.19B | $2.38B | $2.66B | +8.9% |
| Operating income | $932.5M | $899.8M | $1.10B | $1.14B | $1.36B | +10.0% |
| Net income | $744.8M | $679.1M | $845.0M | $887.9M | $1.06B | +9.2% |
| EPS (diluted) | — | $8.03 | $10.06 | $10.67 | $13.08 | +17.7% |
| EBITDA | $1.04B | $1.01B | $1.22B | $1.27B | $1.51B | +9.8% |
| R&D | $161.0M | $254.8M | $191.0M | $219.8M | $251.2M | +11.8% |
| SG&A | $796.4M | $850.8M | $901.9M | $1.03B | $1.05B | +7.1% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 4,303,702,000 |
|---|---|
| Cost of revenue | 1,644,123,000 |
| Gross profit | 2,659,579,000 |
| Operating expenses | 1,299,548,000 |
| Operating income | 1,360,031,000 |
| Non-operating items and tax | -300,567,000 |
| Net income | 1,059,464,000 |
| Total assets | 3,350,759,000 |
|---|---|
| Cash | 180,070,000 |
| Current assets | 1,413,827,000 |
| Total liabilities | 1,745,376,000 |
| Current liabilities | 1,148,814,000 |
| Shareholders’ equity | 1,605,383,000 |
Point-in-time financial data used in the 2026-05-13 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 3.2B | 1B | 744.8M | 755.5M | 636M | 119.5M | 104.6M | 37.8M | 746.8M | — | 23.5M | — | — | — | — | 144.5M | 1B | 29.0% | — | — | — |
| 2022-12-31 | 3.4B | 1B | 679.1M | 543M | 384.1M | 158.8M | 111.9M | 49.8M | 819.7M | — | 430.5M | — | — | — | — | 112.5M | 1.5B | 26.7% | — | — | — |
| 2023-12-31 | 3.7B | 1.2B | 845M | 906.5M | 772.9M | 133.6M | 114.9M | 59.7M | 71.9M | — | -404M | — | — | — | — | 453.9M | 1.1B | 30.0% | — | 10.4% | — |
| 2024-12-31 | 3.9B | 1.3B | 887.9M | 929M | 798.1M | 130.9M | 129.9M | 60.3M | 837M | — | -75M | — | — | — | — | 288.3M | 986.9M | 29.0% | — | 10.4% | — |
| 2025-12-31 | 4.3B | 1.5B | 1.1B | 1.2B | 1B | 138.2M | 145.2M | 60M | 1.2B | — | -30.4M | — | — | — | — | 180.1M | 976.1M | 31.6% | — | 9.5% | — |
IDXX trades at 32.4x forward earnings against a peer median of 17.2x; EV/EBITDA of 27.8x against a peer median of 16.9x; 6 peers.
| Wait for severe multiple compression and a price closer to the $335.08 fair value midpoint before initiating. |
Alert ifFalls below 1.0x over any trailing twelve-month period
This edition does not contain enough finite inputs to reproduce the lens calculation.
This edition does not contain enough finite inputs to reproduce the lens calculation.
This edition does not contain enough finite inputs to reproduce the lens calculation.
| DHR |
| Danaher Corporation |
| 18.3x |
| 4.7x |
| 16.6x |
| 7.1% |
| 22.9% |
| WAT | Waters Corporation | 21.5x | 9.2x | 27.1x | 5.2% | 11.7% |
| A | Agilent Technologies Inc. | 17.2x | 4.5x | 16.9x | 19.9% | 22.9% |
| NTRA | Natera Inc. | -491.1x | 11.7x | -106.1x | -15.0% | -12.4% |
